Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR

Overview

Osteaoarticular infection due to C. acnes are known to be of late onset, causing chronic infection possibly pauci-symptomatic. Osteaoarticular infection due to C. acnes represents a diagnostic challenge, since C. acnes is slow and difficult to grow, and can also be considered a contaminant.A 16S universal PCR bacteriological diagnosis has been proposed but is lacking of sensitivity. A specific C. acnes PCR was developed in 2010, but is not used routinely.

Full Title of Study: “Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR : Descriptive Study of 6 Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: March 1, 2017

Interventions

  • Other: Prosthetic joint infection with Cutibacterium acnes
    • patients having a prosthesis infection with C.acnes identified by specific PCR

Arms, Groups and Cohorts

  • Prosthetic joint infection with Cutibacterium acnes
    • Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR

Clinical Trial Outcome Measures

Primary Measures

  • Rate of diagnostic delay
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • time between surgery and detection of C. acnes by PCR

Secondary Measures

  • rate of radiologic signs
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • prosthesis loosening or not
  • rate of duration of antibiotherapy
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • measures of duration of the antibiotherapy
  • rate of use of this diagnostic
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • descriptions of patients managed with this diagnostic

Participating in This Clinical Trial

Inclusion Criteria

  • patients having had infection prothesis vith C. acnes identified by PCR Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Principal Investigator: EugĂ©nie MABRUT, clinical research assistant – Hospices Civils de Lyon
  • Overall Official(s)
    • Tristan Ferry, Md,PhD, Study Director, HCL

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.